pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Noxivent
drug
save

nitric oxide

Marketedupdated 3mo ago
by $LIN LINDE PLC
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagAdCom2 co-mentions · 2 sources
  • tag510(k) Clearance2 co-mentions · 2 sources
  • tagRecall2 co-mentions · 2 sources

all catalysts(0)

nothing on the calendar yet

Trials studying nitric oxide

  • phase3NO During CPB in Neonates to Reduce Risk of AKIrecruitingn=40
  • phase2Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitiscompletedn=162
  • phase2Effect of iNO in Patients With Submassive and Massive PEwithdrawn
  • N/AA Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Diseaserecruitingn=16
  • phase2Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Graftscompletedn=23
  • phase3Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infectionterminatedn=1,389
  • phase2Diffuse Optical Monitoring With Inhaled Nitric Oxideactive not recruitingn=40
  • —Inhaled Nitric Oxide for the Treatment of Neonatal Hypoxic Respiratory Failure With Pulmonary Hypertensionrecruitingn=120
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Oct 17, 2026
62 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (67)

  • Jul 22, 2040method-of-use (U-3037)US 11672938
  • Nov 3, 2036patentUS 9770570*PED
  • May 3, 2036method-of-use (U-2148)US 9770570
  • Feb 12, 2036formulationUS 10213572
  • Oct 20, 2035formulationUS 10737051
  • Aug 19, 2035patentUS 9279794*PED
  • Feb 19, 2035formulationUS 9279794
  • Jul 6, 2031patentUS 8291904*PED4.9y
  • Jul 6, 2031patentUS 8291904*PED4.9y
  • Jul 6, 2031patentUS 8573209*PED4.9y
  • Jul 6, 2031patentUS 8573209*PED4.9y
  • Jul 6, 2031patentUS 8573210*PED4.9y
  • Jul 6, 2031patentUS 8573210*PED4.9y
  • Jul 6, 2031patentUS 8776794*PED4.9y
  • Jul 6, 2031patentUS 8776794*PED4.9y
  • Jul 6, 2031patentUS 8776795*PED4.9y
  • Jul 6, 2031patentUS 8776795*PED4.9y
  • Jul 6, 2031patentUS 9265911*PED4.9y
  • Jul 6, 2031patentUS 9295802*PED4.9y
  • Jul 6, 2031patentUS 9408993*PED4.9y
  • Jan 6, 2031formulationUS 82919044.4y
  • Jan 6, 2031formulationUS 82919044.4y
  • Jan 6, 2031formulationUS 85732094.4y
  • Jan 6, 2031formulationUS 85732094.4y
  • Jan 6, 2031formulationUS 85732104.4y
  • Jan 6, 2031formulationUS 85732104.4y
  • Jan 6, 2031formulationUS 87767944.4y
  • Jan 6, 2031formulationUS 87767944.4y
  • Jan 6, 2031formulationUS 87767954.4y
  • Jan 6, 2031formulationUS 87767954.4y
  • Jan 6, 2031formulationUS 92659114.4y
  • Jan 6, 2031formulationUS 92958024.4y
  • Jan 6, 2031formulationUS 94089934.4y
  • Jul 14, 2030formulationUS 86077853.9y
  • Jun 21, 2030formulationUS 111036693.8y
  • Dec 30, 2029patentUS 11931377*PED3.4y
  • Dec 30, 2029patentUS 8282966*PED3.4y
  • Dec 30, 2029patentUS 8282966*PED3.4y
  • Dec 30, 2029patentUS 8293284*PED3.4y
  • Dec 30, 2029patentUS 8293284*PED3.4y
  • Dec 30, 2029patentUS 8431163*PED3.4y
  • Dec 30, 2029patentUS 8431163*PED3.4y
  • Dec 30, 2029patentUS 8795741*PED3.4y
  • Dec 30, 2029patentUS 8795741*PED3.4y
  • Dec 30, 2029patentUS 8846112*PED3.4y
  • Dec 30, 2029patentUS 8846112*PED3.4y
  • Sep 21, 2029formulationUS 115112523.1y
  • Aug 13, 2029formulationUS 109260543.0y
  • Aug 13, 2029formulationUS 89440493.0y
  • Aug 13, 2029method-of-use (U-2793)US 96040283.0y
  • Jun 30, 2029compositionUS 119313772.9y
  • Jun 30, 2029compositionUS 119313772.9y
  • Jun 30, 2029method-of-use (U-1286)US 82829662.9y
  • Jun 30, 2029method-of-use (U-1286)US 82829662.9y
  • Jun 30, 2029method-of-use (U-1286)US 82932842.9y
  • Jun 30, 2029method-of-use (U-1286)US 82932842.9y
  • Jun 30, 2029method-of-use (U-1286)US 84311632.9y
  • Jun 30, 2029method-of-use (U-1286)US 84311632.9y
  • Jun 30, 2029method-of-use (U-1286)US 87957412.9y
  • Jun 30, 2029method-of-use (U-1286)US 87957412.9y
  • Jun 30, 2029method-of-use (U-1286)US 88461122.9y
  • Jun 30, 2029method-of-use (U-1286)US 88461122.9y
  • Jan 28, 2029formulationUS 97015382.5y
  • Apr 21, 2027formulationUS 7560076248d
  • Oct 17, 2026formulationUS 761859462d
  • Oct 17, 2026method-of-use (U-3037)US 794722762d
  • Jan 18, 2026method-of-use (U-3037)US 8057742

News(1)

  • The hidden history of BPC-157, a favorite MAHA peptide
    A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.
    stat · 2mo ago
brand
Noxivent
generic
nitric oxide
indication
Hypoxemic Respiratory Failure (Type I)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 22m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?